Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$113.09 USD

113.09
11,127,844

-1.64 (-1.43%)

Updated Sep 26, 2024 04:00 PM ET

After-Market: $113.01 -0.08 (-0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth A Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 17% (44 out of 252)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

The Zacks Analyst Blog Highlights: Merck, Tractor Supply, IDEXX and CVS

Lilly's Study on Higher Doses of Trulicity Meets Endpoint

Lilly's (LLY) phase III study evaluating higher doses of Trulicity meets primary and secondary efficacy endpoints.

FDA Accepts Sanofi's BLA for Meningitis Vaccine to Review

The FDA accepts for review Sanofi's (SNY) BLA for MenQuadfi, a meningococcal vaccine candidate, presently under development to prevent meningococcal meningitis.

Bayer Sets Up Special Committee to Tackle Glyphosate Lawsuits

Activist investor, Elliott Advisors, discloses a 1.1-billion-euro ($1.3 billion) stake in Bayer (BAYRY). It forms a new committee and hires U.S. lawyer Beisner to fight its glyphosate litigations.

Sejuti Banerjea headshot

Is Allergan a Good Deal for AbbVie?

AbbVie is dishing out $63 billion in stock and cash for Allergan, provided it gets regulatory approval.

Tirthankar Chakraborty headshot

4 Stocks to Make the Most of the Growing Love for Pets

With the U.S. pet industry poised to grow 3.9% to a record $75.4 billion this year, here are few stocks that could gain from the growing love for animals.

Merck (MRK) Stock Moves -0.33%: What You Should Know

Merck (MRK) closed the most recent trading day at $85.23, moving -0.33% from the previous trading session.

Bristol-Myers to Sell Otezla for Celgene Merger, Shares Down

Bristol-Myers (BMY) declines as it announces to sell Otezla to settle FTC concerns, while Opdivo fails in liver cancer study.

The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa

The Zacks Analyst Blog Highlights: Microsoft, Chevron, Cisco, Merck and Visa

Neena Mishra headshot

Why These Innovative Biotech ETFs Are Soaring

Strong M&A activity has sent shares of many small, innovative biotech companies surging

Will Pharmacy International Hit Walgreens (WBA) Q3 Earnings?

Challenging market conditions, especially in retail, causes a slowdown in the Retail Pharmacy International division at Walgreens Boots (WBA).

Verastem Up on Positive Data From Early-Stage Copiktra Study

Verastem (VSTM) presents encouraging data from an early-stage study evaluating its recently approved drug, Copiktra, for treating peripheral T-cell lymphoma.

Tirthankar Chakraborty headshot

Dow on Pace for Best June: 5 Blue Chip Stocks to Buy

Dow eyes best June in 80 years as investors cheer the Fed's shift to a more dovish stance.

Novo Nordisk's Haemophilia A Drug Esperoct Gets EU Approval

Novo Nordisk's (NVO) Esperoct gets EU approval for the treatment of adolescents (less-than or equal-to 12 years of age) and adults with haemophilia A.

Sanofi/Regeneron's Asthma Candidate Meets Goal in Study

Sanofi/Regeneron's IL-33 antibody REGN3500 meets primary endpoint in phase II study in asthma. It does not show increased benefit compared to Dupixent.

Swarup Gupta headshot

Dow 30 Stock Roundup: Boeing's $6.5B Air Force Contract, Pfizer to Buy Array BioPharma

The index enjoyed another week of strong gains after the Federal Reserve indicated that a rate cut would likely occur next month.

Are You Looking for a High-Growth Dividend Stock? Merck (MRK) Could Be a Great Choice

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Merck (MRK) have what it takes? Let's find out.

Kinjel Shah headshot

Pharma Stock Roundup: PFE to Buy ARRY, RHHBY, MRK, AZN Drugs Get Regulatory Nod

Pfizer (PFE) announces definitive deal buy Array BioPharma. Merck (MRK), Roche (RHHBY) and AstraZeneca (AZN) win approvals for new drugs/line extensions.

Are You Looking for a Top Momentum Pick? Why Merck (MRK) is a Great Choice

Does Merck (MRK) have what it takes to be a top stock pick for momentum investors? Let's find out.

Stock Market News For Jun 20, 2019

Wall Street closed higher on Wednesday after the Fed kept the federal fund target rate unchanged.

AstraZeneca's Triple-Combo COPD Inhaler Gets Japan's Nod

AstraZeneca (AZN) gets approval in Japan for PT010, its triple-combo inhaler and Bevespi Aerosphere, a fixed-dose LABA/LAMA inhaler, both to treat COPD.

Merck's Keytruda Gets 2nd Label Expansion Approval in June

Merck (MRK) receives FDA approval for Keytruda's label expansion in small cell lung cancer indication, marking the drug's first approval in this indication.

Merck (MRK) Outpaces Stock Market Gains: What You Should Know

Merck (MRK) closed at $84.45 in the latest trading session, marking a +1.38% move from the prior day.

Novo Nordisk's Victoza Gets FDA Nod for Pediatric Patients

Novo Nordisk's (NVO) Victoza gets FDA approval for the treatment of pediatric patients aged 10 years or older with type II diabetes.

AstraZeneca/Merck's Lynparza Wins EU Nod for First-Line Use

AstraZeneca (AZN) and Merck's PARP inhibitor, Lynparza, gets approval in EU as a front-line therapy for BRCA-mutated advanced ovarian cancer.